entertainment -WSS

entertainment

author：entertainment 2025-09-28 06:48:47 - browse：7

An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT — ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Vertex Pharmaceuticals may move headquarters in Boston

focus

WSS

Abortion pill case raises question: who can sue the FDA?

Police still searching for prisoner who escaped from NYC hospital

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Emergent cuts jobs, executive role in business shake

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

South Korea throws huge K

explore

entertainment

Wikipedia

Drug repurposing or repositioning? The language matters

Wegovy trial has doctors encouraged over new possibilities

Malaria cases in Florida and Texas: Here’s what you need to know

Patient advocates debate FDA's accelerated approval process

Activists slam private health insurers over coverage restrictions

There's no autism epidemic. It's an autism diagnosis epidemic

Novavax promises a turnaround & Lilly roils the obesity market

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Heart attack and stroke risk calculators need revising

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

leisure time

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Wegovy trial has doctors encouraged over new possibilities

Maui's cultural, historic landmarks damaged in the devastating wildfires

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Washington mulls new rules to avert another Change Healthcare

There's no autism epidemic. It's an autism diagnosis epidemic

focus

explore

leisure time

explore